BTIG analyst Justin Zelin names Immunocore (IMCR) as his BTIG Top Pick for first half of 2023, replacing Adicet Bio (ACET) on that list. The company has surprised observers of the field of TCR therapy with multiple corporate updates in 2022, led primarily by approval of lead asset KIMMTRAK, or tebentafusp, in January 2022 which was followed by strong revenue growth and distribution across international regions, the analyst tells investors in a research note. Zelin has a Buy rating and a $85 price target on the stock.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ACET:
- Adicet Bio Stock Craters on Phase 1 Clinical Data
- Adicet Bio price target raised to $38 from $34 at H.C. Wainwright
- Adicet Bio reports data from ongoing ADI-001 Phase 1 trial
- Oppenheimer emerging biotech analysts to hold analyst/industry conference call
- Adicet Bio appoints Nancy Boman, M.D Chief Regulatory Officer
